Signal Radar
Evidence, policy, regulation, reimbursement, technology and institutional shifts—scored by impact, immediacy, P4L relevance, novelty and adoption leverage.
FDA selected Dexcom's Glucose Health Program for the TEMPO pilot. The intended use is tied to ACCESS clinical use areas and will be evaluated using real-world data while the program is offered through ACCESS participants.
Decision implication: Digital-health companies should evaluate whether product evidence, use case, outcome measures, and care model can align with ACCESS/TEMPO-style pathways.
CMS's Medicare App Library now describes vetted patient-facing digital health options and explicitly includes Conversational AI Assistants plus Diabetes & Obesity Prevention and Management among supported use cases.
Decision implication: Digital-health products should treat CMS ecosystem eligibility, identity, evidence, privacy, usability, interoperability, and AI disclosure as potential distribution requirements—not afterthoughts.
CMS's interoperability framework says numerous early adopters reached general availability in July 2026 across CMS Aligned Networks, providers, EHRs, payers, and patient-facing apps.
Decision implication: Map which entities are actually live, which interoperability dependencies they satisfy, and where adoption bottlenecks now move from data access to product/evidence/workflow.
FDA's current TEMPO participant table lists Cadence Solutions' HypertensionOS and Dexcom's Glucose Health Program, expanding the pilot beyond the initial announced participant.
Decision implication: Monitor whether participant expansion reveals a repeatable regulatory-adoption pathway for technology-enabled chronic care.
The CY 2027 PFS proposed rule would require established patients and an initiating visit for RPM/RTM, restrict payment when monitoring is delivered by contractors rather than practice-employed clinical staff, and seeks comment on bundling codes into new HCPCS G-codes.
Decision implication: Scenario-model contractor-dependent and device-cost-dependent RPM/RTM business models against proposed policy changes.
CMS reports more than 150 health care organizations accepted to participate in ACCESS, with many organizations bringing technology-supported chronic-care options into Original Medicare.
Decision implication: Map accepted organizations by track, geography, technology model, and partnership potential; identify who becomes an adoption gateway.
ARPA-H's ADVOCATE program is designed to develop clinical AI agents that can autonomously support and adjust aspects of cardiovascular care, alongside a supervisory AI overseer.
Decision implication: Create a dedicated agentic-AI adoption standard covering authority boundaries, human escalation, post-deployment monitoring, evidence, liability, workflow, and regulatory status.
FDA announced steps to explore real-time clinical trials using AI and data science to increase the speed of data flow, safety monitoring, and decision-making.
Decision implication: Monitor whether real-time trial methods become reusable regulatory infrastructure for digital health, therapeutics, and healthspan studies.
ARPA-H launched IGoR to build rigorous AI-enabled research ecosystems that generate hypotheses, run experiments, refine biological models, and accelerate therapeutic discovery.
Decision implication: Track standards, shared protocols, validated speed/quality gains, and whether the model becomes transferable to aging biology and preventive science.
ACCESS supports technology-enabled chronic care with outcome-aligned payment, structured care updates to referring clinicians, and a requirement for participants to connect to aligned networks or HIEs by July 2027.
Decision implication: Treat interoperability and clinician coordination as adoption requirements, not downstream integrations.
FDA's Digital Health Center of Excellence highlights real-world AI performance evaluation, including drift, clinical outcomes, user behavior, infrastructure, and post-deployment monitoring as core lifecycle issues.
Decision implication: Add real-world monitoring, drift detection, human-AI interaction, and response protocols to P4L's AI adoption/evidence standard.
The HTI-5 proposed rule describes a future FHIR foundation for AI-enabled interoperability and proposes clarifying information-blocking definitions to include automated means of access, potentially including autonomous AI systems.
Decision implication: Track final-rule language and design P4L's agentic-AI adoption framework around explicit data-access rights, governance, authentication, provenance, and human authority.
ARPA-H funded seven PROSPR teams to identify early aging markers, build healthspan measures, and test interventions using accelerated and decentralized trial designs.
Decision implication: Track biomarkers, endpoint qualification, trial methods, regulatory precedents, and commercialization pathways created by PROSPR.
Stanford-led THRIVE will harmonize existing datasets to generate a PROSPR-IC healthspan score and test its accuracy and intervenability in a one-year lifestyle intervention supported by in-home digital assessment.
Decision implication: Track the construction, validation, endpoint properties, and public availability of the PROSPR-IC score.
The VITAL-H team plans a phase 3 hybrid trial evaluating repurposed FDA-approved drugs including an SGLT2 inhibitor, rapamycin, and semaglutide in an effort to establish a regulatory path for therapeutics targeting aging outcomes.
Decision implication: Track protocol, endpoints, regulatory interactions, safety management, and whether results support an aging/healthspan indication pathway.
FDA announced a funding opportunity open July 20–August 20, 2026 for selected applicants to explore digital health technologies such as actigraphy, photography, and contactless sensors in drug development.
Decision implication: Track funded projects, measure-validation methods, endpoint acceptability, and resulting guidance or precedents relevant to healthspan and remote measurement.
ASTP/ONC announced 2026-approved SVAP standards including USCDI v6, expanding the standardized data available for exchange across health IT systems.
Decision implication: Update data-readiness requirements in P4L's Adoption Diagnostic and monitor which data classes become practically available through certified systems and aligned networks.
CMS's May 2026 learning update highlights OIG findings that about 43% of Medicare enrollees receiving RPM did not receive all three components, reinforcing oversight and billing concerns.
Decision implication: Add compliance/appropriate-use evidence to the RPM adoption diagnostic and treat unusually weak component delivery as a risk signal for vendors and practices.
FDA states that CDER has seen significant growth in drug application submissions using AI components across nonclinical, clinical, postmarketing, and manufacturing phases.
Decision implication: Track where FDA expectations become more explicit by phase and build those requirements into evidence/adoption readiness for AI-enabled life-science products.
FDA maintains a public list intended to identify AI-enabled medical devices authorized for marketing in the United States and to provide transparency into the regulated landscape.
Decision implication: Ingest the authorized-device list into P4L's Intelligence Graph and compare authorization with real-world adoption, evidence, workflow, and postmarket monitoring.
ARPA-H awarded Linnaeus Therapeutics up to $21.9 million to test whether a once-daily GPER agonist with an established safety profile and cardiometabolic benefits improves aging outcomes.
Decision implication: Track outcome selection, human trial design, safety, biomarker changes, and whether results support broader healthspan claims.
CMS describes 2027-2028 policy steps that make electronic prior authorization a more central interoperability and quality-measure requirement across Medicare workflows.
Decision implication: Include prior-authorization and interoperability readiness in adoption diagnostics for technologies that depend on covered services or medication access.
NIA plans the Fifth Geroscience Summit for December 2-3, 2026 to assess progress, knowledge gaps, and future directions in geroscience with a focus on health.
Decision implication: Create a pre-summit issue map and post-summit change analysis for P4L Brief and Evidence Explorer.
ARPA-H announced up to $28 million in small-business awards spanning wearables, artificial intelligence, diagnostic tools, and gene therapies.
Decision implication: Add funded companies to the Intelligence Graph and track which technologies cross from R&D into clinical validation and institutional adoption.
CMS's January 2026 Medicare learning update states that starting in CY 2026, services will be added to the Medicare telehealth services list only on a permanent basis.
Decision implication: For telehealth products, distinguish temporary flexibilities from durable coverage and map each use case to permanent service eligibility.